Behavioral Neuroscience
June 15, 2023
Caitlyn J Bartsch, Sophia Aaflaq, Jessica T. Jacobs et al.
Ketamine is a dissociative anesthetic that has been shown to have antidepressant effects in humans and has been proposed as a potential treatment for mood disorders such as PTSD and aggression. However, previous studies from our lab and others have demonstrated that ketamine’s effects are highly context- and dose-dependent. In a recent study, we found that 10 mg/kg ketamine could exacerbate the...
Frontiers in Neuroscience
June 12, 2023
Elena Argento, Egiroh Omene, Alexandra Jaeger et al.
10 citations
Functional seizures, a primary subtype of functional neurological disorder (FND), are a known cause of serious neurological disability with an increasing awareness of their impact amongst the neuroscience community. Situated at the intersection of neurology and psychiatry, FND is characterized by a range of alterations in motor, sensory or cognitive performance, such as abnormal movements, limb...
June 9, 2023
Mika Turkia
3 citations
preprint
This article presents the case of a young woman in her mid-twenties with a history of depression since childhood. She lived with a mother who failed to take care of her. The patient cared for the emotional needs of the mother instead of the mother caring for the daughter's needs. Her father was mostly absent. Already around the age of thirteen, the patient was severely depressed and was...
British Journal of Guidance & Counselling
June 8, 2023
Fuat Can Çalışkan, Sibel Akmehmet-Şekerler, Zeynep Kızıltepe et al.
ABSTRACT Along with anxiety and depression, mindfulness has recently gained attention among the predictors of college adjustment. This study conducted in Türkiye, investigated the relationship between mindfulness and college adjustment through the mediating role of depression and anxiety. Data were collected using the Depression Anxiety Stress Scale, the Mindful Attention Awareness Scale, and...
Bipolar Disorders
June 8, 2023
The authors have declared no conflict of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Journal of Education, Health and Sport
June 7, 2023
Paulina Czuchryta, Rafał Babiak, Karolina Bajak et al.
Introduction and purpose: The problem of major depression disorder (MDD) affects more and more people. In a few years, it may become the most common disease after cardiovascular diseases and cancer. MDD are manifested by a depressed mood, decreased energy, loss of interest and the ability to enjoy life, as well as a number of other additional symptoms. Untreated MDD can lead to disability. This...
Brain Sciences
June 4, 2023
Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni et al.
46 citations
Bipolar depression remains a clinical challenge with a quarter of patients failing to respond to initial conventional treatments. Although ketamine has been extensively studied in unipolar depression, its role in bipolar disorder remains inconclusive. The aim of our scoping review was to comprehensively synthesize the current clinical literature around ketamine use in bipolar depression. A...
Frontiers in Psychiatry
June 2, 2023
Depression is among the most common mental health disorders worldwide and treatment resistant depression (TRD) represents a major challenge for both patients and clinicians. In recent years ketamine has received attention as an antidepressant agent, demonstrating promising results in TRD in adults. To date, few attempts have been made in treating adolescent TRD with ketamine and none have used...
International Journal of Surgery Global Health
June 2, 2023
Tooba Noor, Areej Shakil, Aimen Waqar Khan et al.
The COVID-19 pandemic has resulted in a surge in depression cases, a pervasive and debilitating mental illness1. This trend is evident in the increased prescriptions for antidepressants. Depression is a chronic condition that affects a significant proportion of the global population, with ~280 million people, or about 3.8%, suffering from it. As a result, it is a significant mental health...
Cureus
June 2023
Tarika Nagi, Amit Jagtiani, Saurabh Somvanshi et al.
Intravenous ketamine infusions in subanesthetic doses have been shown to rapidly alleviate depressive symptoms. However, the efficacy of ketamine as an anesthetic during electroconvulsive therapy (ECT) for major depression has not yet been answered by a large randomized control trial (RCT). This scoping review aims to examine the available literature to determine whether the dose of ketamine...